key: cord-0875607-4i9c4ns6
authors: Ehsan, Goudarzi; Fateme, Yousefimoghaddam; Alireza, Ramandi; Isa, Khaheshi
title: COVID-19 and peripheral artery thrombosis: A mini review
date: 2021-09-24
journal: Curr Probl Cardiol
DOI: 10.1016/j.cpcardiol.2021.100992
sha: ad0a68de5b2c9ffdfbf6f3099c352e11b9dcfe6d
doc_id: 875607
cord_uid: 4i9c4ns6

For more than two years, health care systems have been floundering in a massive crisis of coronavirus disease 2019 (COVID-19) pandemic. while acute respiratory distress syndrome is the main complication in patients with COVID-19, as the pandemic continues, more data about the non-respiratory effects of the coronavirus is obtained, including developing Coagulopathy-related manifestations, in the form of venous and arterial thromboembolism. Although arterial thrombosis a rare complication of this disease, it proves to be an effective factor in the mortality and morbidity of COVID-19 patients. The pathophysiology of thrombosis reveals a complex relation between hemostasis and immune system that can be disrupted by COVID-19. Thrombectomy, anticoagulant therapy, and thrombolysis are the main treatments in these patients. In addition, appropriate thromboprophylaxis treatment should be considered in COVID-19 patients. In this article, we have successfully reviewed the arterial thrombotic events in patients reported around the world, including the diagnostic and management method of choice.

shows a wide spectrum of clinical presentation and continues to intrigue medical professionals with its variety of symptoms ranging from mostly asymptomatic to fatal conditions following multi-organ involvement mainly involving respiratory system. [2] Prior outbursts of coronaviruses, (i.e. severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) and Middle-Eastern respiratory syndrome (MERS) ) have shown a significant association with increased risk of thrombosis. [3] Likewise, COVID-19 appears to generate a prothrombotic state as evidenced by a surge in global pulmonary embolisms, deep vein thrombosis, cardiac thrombosis, catheter related thrombosis, and arterial thrombosis. Moreover, Laboratory tests of COVID-19 patients demonstrate the prothrombic state of patients; including increased level of D-dimer, fibrinogen, factor VIII, and von Willebrand factor. [4] Although there has been an extensive focus on deep vein thrombosis and pulmonary embolism as the complications of the COVID-19, there are limited number of studies in fields of peripheral arterial thrombosis. Furthermore, the studies performed on arterial thrombotic events are majorly along with the studies of venous thrombo-embolism, which decreases the focus on diagnostic and treatment options for this complication. We aim to investigate the literature focusing on arterial thrombotic complications, including the location, method of localization and diagnosis, and management procedure.

In order to achieve an accelerated qualitative analysis, we performed PubMed search using MeSH (medical subject headings) terms in search strategies mentioned below:

, "Thrombosis"[Mesh], and "Blood Coagulation"[Mesh], (3) combination and snowballing of (1) and (2) . We select the relevant articles to arterial thrombotic events for the purpose of this review. In order to decrease the level of bias, data were extracted independently by FY and EG in a double data extraction method, followed by a thorough re-assessment of included articles by AR and IK.

COVID-19 may lead to an increased risk of thrombotic events through various pathophysiological means (figure 1):

1-Disseminated intravascular coagulation: Disseminated intravascular coagulation (DIC) is commonly observed in critically ill patients. Generally, it elicits the initiation of the tissue factor pathway of the coagulation cascade and deposition of platelet-fibrin thrombi in the microvasculature. This ultimately consummates the platelets and the procoagulant factors, resulting in a correlated bleeding diathesis. [5] 2-Inflammatory cytokines: Excessive cytokine release is assumed to be the cause of the severe illness noted in adolescent patients without prior comorbidities. Higher serum levels of several inflammatory cytokines and chemokines have been related to severe illness and death in several studies. [6] 3-Macrophage activation syndrome: Macrophage activation syndrome (MAS) may contribute to the aspects of the cytokine storm and hypercoagulopathy observed in COVID-19 patients. MAS occurs when activated antigen presenting cells cannot be lysed by CD8+ T cells or natural killer cells. After an initial inflammatory trigger, elevated IL-6 has been shown to diminish natural killer cells cytolytic capacity. Hence, there is a substantial interaction among innate and adaptive immune system that additionally promotes cytokine storm, phagocytosis, and multi-organ dysfunction. [7] 4-Complement system activation: Complement system activation may also recruit and activate leukocytes, resulting in significant release of the proinflammatory cytokines (i.e., IL-1, IL-6, IL-8, and interferon-γ) and promoting microvascular damage. Complement system is strongly activated in sepsis and inhibiting the complement cascade can improve coagulopathy and endothelial dysfunction in animal models with sepsis. [8] 5-Renin angiotensin system (RAS) overactivation: Angiotensin-converting enzyme 2 (ACE2) is a membrane-bound protein mainly distributed in the lungs, heart, arteries, and veins. [9] Angiotensin II(Ang II), the product of ACE2, promotes vasoconstriction, proinflammation, and prothrombotic effects via the Angiotensin II receptor type I (AT1R) and Angiotensin II receptor type IV (AT4R). ACE2 inhibits the RAS activity in two ways. First, ACE2 degrades Ang I and Ang II, reducing the substrate for activation of AT1R via the classical RAS. Secondly, Ang II is directly degraded into Angiotensin-(1-7), a vasodilatory peptide with antiinflammatory effects. COVID-19 uses ACE2 for cellular entry. Through this process, it is assumed that the down-regulation of pulmonary of ACE2 is followed by moving the balance towards proinflammatory and prothrombotic effects of Ang II and AT1R. [10] 6-Hypoxia: Hypoxia-inducible factors (HIFs) can activate platelets and coagulation factors, causing an increased expression of tissue factor and plasminogen activator inhibitor 1(PAI-1), meanwhile inhibiting the endogenous anticoagulant protein leading to worsening of the hypercoagulable state. [11] 

We reviewed 46 patients ranging from 24 to 83 years old with average and median of 61.4 and 61 years old, respectively. Covid 19 infection was confirmed in all patients included in the study by using standard methods that are acceptable worldwide; including polymerase chain reaction (PCR), chest X ray, chest computer tomography scan (CT), and serological tests. Details of each case is provided in table 1. Male sex, smoking, hypertension, diabetes, chronic kidney disease (CKD), and obesity are corelated with preexisting endothelial dysfunction which is a risk factor for thrombosis. [12, 13] We illustrated these risk factors in figure 2 . We divided these thromboses to five groups based on location: 1-head and neck, 2aorta, 3-abdomen, 4-upper limb, and 5-lower limb. Each group includes several arteries which is illustrated bellow:

Head and neck: we reviewed 7 cases of thrombosis in Central retinal artery, ophthalmic artery, internal carotid artery, common carotid, and middle cerebral artery. CT-angiography (CTA) was used as the diagnostic method for 3 patients, CT for 1 patient, and other methods in 3 patients. For treatment, Low Molecular Weight Heparin (LMWH) was given in 3 patients, Unfractionated Heparin (UFH) in 2 patients, and thrombectomy and endarterectomy were performed each in 1 patient.

Thoracic Aorta: We observed 16 cases of arterial thrombosis localized in the thoracic Aorta as a result of covid-19 infection; Of which ascending aorta (n=2), aortic arch (n=6), and descending aorta (n=8) were specifically mentioned as the region of involvement. Two studies did not mention the exact region of the thrombosis. CTA was the method of choice for diagnosis in 9 patients, CT in 6, angiography in 1, and ultrasound in 1 patient. For treatment purposes UFH was given in 6 patients, LMWH in 4, thrombolysis in 4, and thrombectomy in 3. Other treatments that were not commonly used include norepinephrine, clopidogrel, direct oral anticoagulants, and argatroban. Two case reports did not accomplish to address the exact treatment and management method.

Abdomen: We reviewed 20 cases of abdominal thrombosis occurring in abdominal aorta, superior mesenteric, jejunal, ileocolic branch arteries, renal arteries. The most common diagnostic method included CT (n=10) and CTA (n=9), followed by angiography (n=1) and ultrasound (n=1). common treatment choices consisted of thrombectomy (n=10), resection (n=7), UFH administration (n=7), thrombolysis (n=5), clopidogrel (n=2), and LMWH administration (n=2). Less frequent treatments were apixaban, warfarin, vit K antagonist, aspirin, and ecosprin.

Upper limb: We reviewed 5 patients of the upper limb thrombosis in brachiocephalic, subclavian, axillary, brachial, radial, ulnar as a result of covid-19 infection. The diagnostic method was CTA alone (n=2) or CTA and doppler-ultrasound (n=2). UFH (n=3) and LMWH (n=2) were administered to the patients for treatment. Thrombectomy was performed in 3 patients. amputation was carried out in 2 patients.

Lower limb: We reviewed 16 cases of lower limb thrombosis in common iliac, internal, and external iliac, deep, and superficial femoral, popliteal, tibial, and posterior tibial as a result of covid-19 infection. Diagnostic methods included CTA (n=8), ultrasound (n=6), CT (n=4), and angiography (n=1). For management, thrombectomy (n=9) and amputation (n=6) were performed. The remaining patients underwent medical treatment with LMWH (n=3), UFH (n=2), thrombolysis (n=1), and aspirin (n=1).

Overall, there were 4 patients with pulmonary embolism and 8 patients with venous thrombotic events classified in 4 patients with deep vein thrombosis, 3 with inferior/superior mesenteric vein and 1 with portal vein thrombosis. there were also 2 patients with cardiac thrombosis with thrombi located in the ventricles.

Thrombotic events are frequently seen in COVID-19 and contribute to poorer outcome. [7] As for the other reviews have frequently discussed pulmonary embolism, vein thrombosis and cardiovascular thrombotic events, the purpose of this review is to fill the gap in the literature about arterial thrombosis along with future perspectives regarding diagnostic and therapeutic methods. Here we summarized 46 cases of arterial thrombosis categorized into five groups based on location of event.

Cheruiyot et al. reported the majority of the COVID-19 patients with arterial thrombosis have been male patients, and the median age have been 50 years old. [14] However, due to the fact that venous and arterial involvement have not been separated in this literature, the data reported for arterial involvement have been missing the age-sex information. The other possible pitfall in this field is that the prevalence of COVID-19 infection is more in male population and the median age of infection is 50 years old. [3] Hence, it should be further investigated whether the male sex and age is indeed a risk factor for arterial thrombosis, or the predominance of arterial thrombosis in male patients in certain age group is merely a result of age-sex prevalence of COVID-19 infected patients.

Comparing the venous thromboembolism, arterial thrombosis is an uncommon event. Di Minno et al. [15] reported the incidence of venous thrombo-embolism 24.3-39.2% in a meta-analysis, whereas the incidence of arterial thrombosis is 4.4%. [14] Higher D-dimer value is mentioned as a risk factor of both venous and arterial thrombo-embolic events. [15, 16] Both asymptomatic and symptomatic venous thrombosis show high levels of d-Dimer. Contrarily, there are limitations in studying d-Dimer level in asymptomatic arterial thrombosis, as a result of lower prevalence rate of arterial thrombosis in COVID-19 patients.

Most frequently used diagnostic methods were CTA, CT, and ultrasound. CTA was the most used diagnostic method with 24 times in all discussed categories, followed by CT (n=13), and ultrasound (n=9). The therapeutic method of choice was thrombectomy with total of 18 times. In the next place UFH with 13 and LMWH with 12 times were used. Additionally, amputation or resection were performed 14 times and thrombolysis therapy 7 times.

Elevated levels of D-dimer were seen at least in 31 patients. Previously collected data clearly suggests that an elevated D-dimer, and presence of coagulopathy, indicates a poorer prognosis in COVID-19 patients. [2, 17] Heightened clinical vigilances and observation of D-dimer levels are needed in hospitalized covid-19 patients, although the decision-making process should be case-based for every individual. Thrombosis is a major complication in COVID-19 patients with optimal thromboprophylaxis being unknown. At least 14 patients were given anticoagulant as prophylaxis which was proven inadequate and highlights the necessity of novel or additional therapeutic approaches.

☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 

World Health Organization website

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past

Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis

Utility of thromboelastography and/or thromboelastometry in adults with sepsis: a systematic review

Correlation analysis between disease severity and clinical and biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: a descriptive study

Thrombosis in COVID-19

Crosstalk between the coagulation and complement systems in sepsis

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Immunothrombosis in Acute Respiratory Distress Syndrome: Cross Talks between Inflammation and Coagulation. Respiration

Endothelial cell infection and endotheliitis in COVID-19. The Lancet

Thrombosis in the uremic milieu--emerging role of "thrombolome

Arterial thrombosis in coronavirus disease 2019 patients: a rapid systematic review. Annals of vascular surgery

COVID-19 and venous thromboembolism: a meta-analysis of literature studies. in Seminars in thrombosis and hemostasis

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet

Unique case of central retinal artery occlusion secondary to COVID-19 disease. IDCases

Case Report: Central Retinal Artery Occlusion in a COVID-19 Patient

Symptomatic Common Carotid Free-Floating Thrombus in a COVID-19 Patient, Case Report and Literature Review

Aortic thrombus in patients with severe COVID-19: review of three cases

COVID-19-Related Aortic Thrombosis: A Report of Four Cases. Annals of Vascular Surgery

Systemic arterial thrombosis and acute mesenteric ischemia in a patient with COVID-19

Severe arterial thrombosis associated with Covid-19 infection

Severe acute respiratory syndrome coronavirus 2-induced acute aortic occlusion: a case report

Aortic Arch Thrombus and Pulmonary Embolism in a COVID-19 Patient

Case of right ventricular and aortic thrombi in a patient with severe COVID-19

Severe Aortic Thrombosis in the Early Period after COVID-19: Two Cases

Case Report: COVID-19 Associated Renal Infarction and Ascending Aortic Thrombosis

Extensive Aortic Thrombosis in a Patient With COVID-19

Acute aorto-iliac and mesenteric arterial thromboses as presenting features of COVID-19

Acute aortoiliac occlusion in a patient with novel coronavirus disease-2019

Systemic Thrombolysis as Initial Treatment of COVID-19 Associated Acute Aortoiliac and Lower Extremity Arterial Thrombosis. Annals of Vascular Surgery

Extensive Arterial Thrombosis in Covid-19. The American journal of cardiology

COVID-19 as the cause of thrombosis: recognising COVID-19 infection in apparently asymptomatic patients

Superior Mesenteric Artery Thrombosis in a Patient with COVID-19: A Unique Presentation

Superior Mesenteric Arterial and Venous Thrombosis in COVID-19. The Journal of emergency medicine

Mostafa El Hajjam, Robert-Yves Carlier, Arterial and venous abdominal thrombosis in a 79-year-old woman with COVID-19 pneumonia

Arterial Mesenteric Thrombosis as a Complication of SARS-CoV-2 Infection

SARS-CoV-2-related Hypercoagulable State Leading to Ischemic Enteritis Secondary to Superior Mesenteric Artery Thrombosis

Superior Mesenteric Artery Thrombosis in COVID-19 Pneumonia: an Underestimated Diagnosis-First Case Report in Asia

Axillary artery thrombosis resulting in upper limb amputation as a COVID-19 sequela

A case of rapidly progressive upper limb ischemic necrosis in a patient with COVID-19

Acute upper limb ischemia in a patient with COVID-19

Implications of COVID-19-associated Coagulopathy on Reconstructive Surgery: A Case of Ongoing Tissue Necrosis

Images in Vascular Medicine: Acute peripheral artery occlusion and ischemic stroke in a patient with COVID-19

Bilateral Acute Cardioembolic Limb Ischemia After Coronavirus Disease 2019 Pneumonia in a Lung Transplant Recipient: A Case Report

Ischemic Necrosis of Lower Extremity in COVID-19: A Case Report

Femoral Arterial Thrombosis in a Young Adult after Nonsevere COVID-19. Annals of Vascular Surgery

Isolated posterior tibial artery thrombosis after nonsevere SARS-CoV-2 infection. Revista da Sociedade Brasileira de Medicina Tropical